by Corporate Communications/February 14, 2023
Boehringer Ingelheim collaborates with Alizent on novel cold chain tracking solution for poultry vaccines
Continuous monitoring will help ensure product integrity and supply performance
DULUTH, Ga. (FEB. 14, 2023) – Boehringer Ingelheim Animal Health USA Inc. announced they have entered a strategic collaboration with Alizent, a subsidiary of Air Liquide, to implement an innovative cold chain tracking solution to enhance poultry vaccine supply chain management. Some poultry vaccines are frozen at -200°C (-328°F) and shipped in containers, known as Dewars, filled with liquid nitrogen (LN2) to maintain the cold temperature during transit and protect the efficacy of live cells inside the vaccines. The collaboration taps into the growing interconnectivity of the Internet of Things (IoT) by using Alizent’s SmartDewar IoT platform to track Dewars housing liquid nitrogen and cryogenic samples, such as poultry vaccines. It will also monitor the level of liquid nitrogen in the container and provide temperature alerts. The SmartDewar technology gives Boehringer Ingelheim Animal Health tools to constantly monitor the cold chain to help ensure product integrity, improve efficiency of the supply network, and accelerate the development of transformative digital solutions.
“This novel cryogenic cold chain tracking solution developed with Alizent brings the opportunity for continuous monitoring and greater visibility of the supply chain to help ensure product integrity and monitor supply network performance,” said Claudia Garcia, Head of Global Strategic Poultry Marketing, Boehringer Ingelheim Animal Health. “With the convergence of IoT sensors and cloud technologies backed by global wireless connectivity, this new solution can be a game changer for the transportation of the vaccine supply supporting poultry producers.”
About Boehringer Ingelheim Animal Health USA
Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.
As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.
Learn more about Boehringer Ingelheim Animal Health USA at bi-animalhealth.com.
Corporate Communications, Boehringer Ingelheim Animal Health